Foreign journal publishes article on Cuban drug NeuroEpo

Havana, December 14 (RHC)-- Cuban Center for Molecular Immunology today highlighted the presence of an article on the drug NeuralCIM (NeuroEPO) developed in the Caribbean island against Alzheimer's disease.  "A new impact of NeuroEpo in scientific journals: a hope for patients with mild or moderate Alzheimer's disease." Underlines a message from the institution on the social network X.

The article is located in BioMed Central, which is part of Springer Nature and was placed in the Alzheimer's Research & Therapy section.

NeuroEPO is a variant of recombinant human erythropoietin formulated for nasal administration whose final development demonstrated that there is a halt in the progression of Alzheimer's disease and that it improves aspects related to the cognitive sphere.

Data from Cuba's Ministry of Public Health show that nearly 170 thousand people in the country suffer from dementia, of which 10 percent are over 65 years of age and make up 1.3 percent of the total population.

The prevalence of this neurodegenerative disease is estimated at 10.2 per 100 Cubans aged 65 or older, and Alzheimer's disease is the most frequent cause.

Cuba today exhibits remarkable progress in the clinical trial of the drug NeuralCIM (NeuroEPO) against Alzheimer's disease, an ailment that affects thousands of people in the world and devastates their families. (Source: Prensa Latina)